Findings

What do systematic reviews say?

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Antioxidants vs placebo

Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · children with trichotillomania

1 finding from 1 review

Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 6 participants
Low

Antioxidants vs placebo

Withdrawals due to adverse events · children with trichotillomania

1 finding from 1 review

Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 6 participants
Low

Antipsychotics vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with trichotillomania

Antipsychotics may leads to higher treatment responseaClinical Global Impressions ‐ Improvement Scale… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
RR 5.08 [1.4, 18.37]
1 study · 25 participants
Low

Antipsychotics vs placebo

Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania

1 finding from 1 review

Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Antipsychotics vs placebo

Withdrawals due to adverse events · adults with trichotillomania

1 finding from 1 review

Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Any dose of lacosamide vs placebo

50% or greater reduction in seizure frequency · adults and children with drug‐resistant focal epilepsy

Any dose of lacosamide leads to higher 50% or greater reduction in seizure frequency compared with placebo (high certainty).

1 finding from 1 review

Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.79 [1.55, 2.08]
5 studies · 2199 participants
High

Any dose of lacosamide vs placebo

Seizure freedom · adults and children with drug‐resistant focal epilepsy

Any dose of lacosamide may leads to higher seizure freedom compared with placebo (low certainty).

1 finding from 1 review

Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.27 [1.35, 3.83]
5 studies · 2199 participants
Low

Any dose of lacosamide vs placebo

Treatment withdrawal · adults and children with drug‐resistant focal epilepsy

Any dose of lacosamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).

1 finding from 1 review

Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.57 [1.24, 1.98]
5 studies · 2199 participants
Moderate

Any dose of lacosamide vs placebo

Dizziness · adults and children with drug‐resistant focal epilepsy

Any dose of lacosamide leads to higher dizziness compared with placebo (high certainty).

1 finding from 1 review

Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.96
5 studies · 2199 participants
High

Any dose of lacosamide vs placebo

Headache · adults and children with drug‐resistant focal epilepsy

Any dose of lacosamide probably leads to higher headache compared with placebo (moderate certainty).

1 finding from 1 review

Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.34
5 studies · 2199 participants
Moderate

Any dose of lacosamide vs placebo

Vomiting · adults and children with drug‐resistant focal epilepsy

Any dose of lacosamide probably leads to higher vomiting compared with placebo (moderate certainty).

1 finding from 1 review

Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.94
5 studies · 2199 participants
Moderate

Any dose of lacosamide vs placebo

Serious adverse events · adults and children with drug‐resistant focal epilepsy

Any dose of lacosamide probably leads to higher serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.53
5 studies · 2199 participants
Moderate

Standard rhGH vs placebo

FEV1 % predicted: absolute change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Low

Standard rhGH vs no treatment

Height velocity (cm/year) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 156 participants
Very low

Standard rhGH vs no treatment

Change in weight (kg) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Very low

Standard rhGH vs no treatment

QoL · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 57 participants
Very low

Standard rhGH vs no treatment

Fasting blood glucose (mg/dL) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 92 participants
Very low

Standard rhGH vs no treatment

Number of pulmonary exacerbations or hospitalisations · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 94 participants
Very low

High‐dose rhGH vs placebo

FEV1 % predicted: absolute change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

FVC (% predicted) Change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low